TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01574326

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevelamer carbonate
Description: 0.8 g sachets of powder for oral suspension or 800 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Description: 0.8 g sachets of powder for oral suspension or 800 mg tablets
Study: NCT00371423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté™-SR
Description: Paclitaxel-Eluting Coronary Stent System

Intervention type: DEVICE
Group type: OTHER
Intervention: TAXUS Liberté™-SR
Description: Paclitaxel-Eluting Coronary Stent System
Study: NCT04360954

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: There is no intervention. This study will test deidentified archived biosamples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: There is no intervention. This study will test deidentified archived biosamples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: There is no intervention. This study will test deidentified archived biosamples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: There is no intervention. This study will test deidentified archived biosamples.
Study: NCT04224311

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra
Description: 0.5 mL dosage of Menactra will be administered by intramuscular injection in the deltoid muscle on day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra
Description: 0.5 mL dosage of Menactra will be administered by intramuscular injection in the deltoid muscle on day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra
Description: 0.5 mL dosage of Menactra will be administered by intramuscular injection in the deltoid muscle on day 0.
Study: NCT04052893

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expanded Mckissock surgery
Description: Expanded Mckissock surgery: (1) According to patient's preoperative imaging results and subjective expectations of their own breast morphology, the incision design and breast surface marking will be performed under the standing position. (2) After general anesthesia, the upper limbs will be abducted, and the upper body will be tilted by 15°-20° to dermatize the labeled skin around and below the areola. (3) The medial and lateral flaps will be dissociated to remove the total gland with nipple and areola preserved. (4) The cutting-edge of nipple-areola complex will be sent for cancer screening. The axillary lymph node biopsy or cleaning will be performed along the outer edge of the pectoralis major muscle. (5) The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified radical mastectomy
Description: The patients will be placed in the supine position. After intravenous anesthesia, the tumor boundary will be marked and the breast will be removed. The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
Study: NCT04334629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Lipid ibuprofen 200 mg
Study: NCT01450839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo tablets and tape
Study: NCT00505531

Intervention type: DRUG
Intervention: Tramadol Extended Release Oral Capsule
Description: Tramadol ER- up to either 200 mg or 300 mg based on randomization

Intervention type: DRUG
Intervention: Tramadol Extended Release Oral Capsule
Description: Tramadol ER- up to either 200 mg or 300 mg based on randomization

Intervention type: DRUG
Intervention: Benadryl
Description: Placebo group will take up to 25 mg of Benadryl
Study: NCT01723852

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D at 30 ug/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D at 10 ug/day
Study: NCT00237198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study: NCT01680705

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Volume Saline Irrigation
Description: High volume saline irrigation (240 ml)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Volume Saline Irrigation
Description: High volume saline irrigation (240 ml)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Volume Saline Irrigation
Description: High volume saline irrigation (240 ml)
Study: NCT01585194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT01957644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Study: NCT03172325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 15 mg Methotrexate is weekly administered to all the patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: At least 1 mg Folic acid is daily administered to all the patients.
Study: NCT01957644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Study: NCT01336920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV
Study: NCT03117101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Study: NCT01806948

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramosetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Study: NCT02630433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Index cholecystectomy
Description: Cholecystectomy performed within 48 hours after inclusion, before discharge after admission for acute biliary pancreatitis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scheduled cholecystectomy
Description: Cholecystectomy performed as a scheduled procedure 6 weeks after the first admission.
Study: NCT03172325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: At least 1 mg Folic acid is daily administered to all the patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 7.5 mg Prednisolone is daily administered to all the patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 7.5 mg Prednisolone is daily administered to all the patients.
Study: NCT04694352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jumping Exercises
Description: Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side Each exercise done for 1 minute, 5 repetitions is session of 1 hour 15minutes
Study: NCT02356744

Intervention type: OTHER
Intervention: Ultrasound
Description: Ultrasound assessment of fetal growth, anomalies , liqour and placenta
Study: NCT04694352

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical therapy
Description: Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping. At least 5 repetitions for each exercise in session of total 1 hour
Study: NCT03051412

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study: NCT02292758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given IV
Study: NCT02357082

Intervention type: RADIATION
Intervention: MRI Scan
Description: MRI scan with Specific Absorption Rate (SAR) limit of 1.5 watts per kilogram of body weight
Study: NCT05098964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pedometer home based rehabilitation
Description: Home based pulmonary rehabilitation for 6 weeks using pedometer Omron HJ 321 pedometer (Omron Healthcare Co Ltd, Kyoto, Japan)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Hospital based exercise training for 6 weeks
Study: NCT02072460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electromyography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: approaches from psychophysics
Study: NCT02829736

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative sealing test
Description: A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative sealing test
Description: A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard post-operative chest tube
Description: A regular chest tube is left in the pleura.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative chest tube removal
Description: Chest tube is removed intraoperatively.
Study: NCT03505294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented training
Description: Task-oriented training consisting of 10 different motor tasks including lower extremity and upper extremity activities will be applied to the training group twice a week for 6 weeks.
Study: NCT04673370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ba Duan Jin
Description: Ba Duan Jin, a traditional Chinese health-preserving technique, combines techniques regulating body, breath and spirit. According to traditional Chinese theory, every movement of Ba Duan Jin has unique effect to different Zang-fu organs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
Study: NCT02076308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and physical therapy
Description: real electroacupuncture

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-electroacupuncture and physical therapy
Description: Sham electroacupuncture
Study: NCT03550170

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teleconference
Description: This intervention arm will be a 6-week, group-based course involving weekly 80-min teleconference sessions. It will be delivered in small groups (6-12 participants) to maximize participants' opportunities for interaction. A program manual divided into 6 sections, 1 for each week that includes worksheets and homework activities will be given to the participants. Occupational therapists will facilitate the sessions. Participants and the OT will dial into 1-800 conference call line on the designated date and time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet
Description: The internet course is similar to the teleconference format. It will occur in a 6-week period and be group based; i.e., 8-12 participants will begin the intervention at the same time and interact with each other during the 6-week period. Participants will be given a username and a password to view a different session each week at a time convenient for them. Each session will include completing practice activities and sharing information (e.g., offering advice and support to one another through the discussion forum). OTs will facilitate the discussions by responding to entries, asking questions, and providing encouragement to complete sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1-to-1, in-person or videoconference
Description: Unlike the teleconference and internet courses, the number and length of sessions for the 1-to-1, in-person or videoconference course will vary over the 6-week period. The OT will cover all 6 topics, but the pace will be tailored to the participants' needs and preferences. Thus, although the topics are consistent, OTs are able to spend more time on topics that participants find pertinent to their situations. The participant and OT will be instructed to meet at least 3 times with at least 7 days between each session.
Study: NCT01229254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: Patients on Amiodarone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban 60 mg
Description: Betrixaban 60 mg once a day with food on Day 0 through Day 25

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban 90 mg
Description: Betrixaban 90 mg once a day with food on Day 0 through Day 25

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban 30 mg
Description: Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
Study: NCT04823455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fresh-frozen humeral head osteochondral allograft reconstruction for reverse Hill-Sachs lesion
Description: Between 2001 and 2018, a total of 12 consecutive patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.
Study: NCT03009435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prophylactic manual rotation
Study: NCT04242303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee replacement
Description: Total knee arthroplasty using standard anterior approach. In the EM group, inertial sensor will be used to perform femoral bone cuts.~In the IM group, conventional intramedullary nail will be used as reference to perform femoral bone cuts.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: Total knee arthroplasty using standard anterior approach. In the EM group, inertial sensor will be used to perform femoral bone cuts.~In the IM group, conventional intramedullary nail will be used as reference to perform femoral bone cuts.
Study: NCT02607475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic telesonography (MELODY Patient System, AdEchoTech)
Description: Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional sonography (EPIQ 5, Philips or LOGIQ E9, GE Healthcare)
Description: Conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare) ultrasound systems.
Study: NCT03537898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's
Description: Lactated Ringer's will be used whenever an isotonic crystalloid is ordered

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normosol
Description: Normosol-R pH 7.4 will be used whenever an isotonic crystalloid is ordered
Study: NCT03008681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Andresen functional removable orthodontic appliance
Description: Included patients were treated for 24 months with a Functional removable orthodontic appliance, the Andresen activator. The initial checks were performed after 6 weeks with subsequent checks being carried out every 8th week, with the final follow-up at 24 months. The patient underwent functional treatment using the activator described in the protocol with midlines coincidence.
Study: NCT03590106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Recovery Support Program
Description: See above
Study: NCT03151460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine Agent
Description: Patients were assessed in two experimental conditions that were performed on different days, with an intersession interval of about one month. In the off condition PD subjects performed the experimental tasks in the morning after 12/18 hours of Dopamine Agent withdrawal. In the on condition they were examined 90-120 minutes after they had taken their first morning dose of levodopa and/or dopamine agonists.
Study: NCT01504945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfusion
Description: 1 bag of packed red blood cells
Study: NCT03388736

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary Medicine
Description: A diffuser containing 120 ml water and 0.1 or 0.3 ml lavender oil (according to arm) will be set into the patients' rooms to mist at least 30 minutes before the patients arrive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary Medicine
Description: A diffuser containing 120 ml water and 0.1 or 0.3 ml lavender oil (according to arm) will be set into the patients' rooms to mist at least 30 minutes before the patients arrive.
Study: NCT00933270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUPERA® Nitinol Stent System
Description: Percutaneous Angioplasty of the Superior Femoral Artery with placement of a SUPERA® Stent at time of PTA
Study: NCT00070317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosulfan Blue
Description: Undergo lymphangiography using isosulfan blue or methylene blue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Mapping
Description: Undergo lymphatic mapping
Study: NCT03619707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
Study: NCT00834990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex sodium
Description: delayed-release 500 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote®
Description: delayed-release 500 mg tablet
Study: NCT04352088

Intervention type: PROCEDURE
Intervention: Nasal provocation test
Description: Allergen extract under controlled conditions will be applied into nasal mucous.
Study: NCT01504945

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infusion
Description: 500 mL of normal saline infusion
Study: NCT00070317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphangiography
Description: Undergo lymphangiography using isosulfan blue or methylene blue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Undergo lymphangiography using isosulfan blue or methylene blue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
Study: NCT04352088

Intervention type: PROCEDURE
Intervention: Nasal provocation test
Description: Allergen extract under controlled conditions will be applied into nasal mucous.

Intervention type: PROCEDURE
Intervention: Nasal provocation test
Description: Allergen extract under controlled conditions will be applied into nasal mucous.
Study: NCT03918590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
Description: NSAID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Theratears tear drop, (Akron, Ann 111 Arbor, MI)
Description: preservative-free Artificial Tears

Intervention type: OTHER
Group type: OTHER
Intervention: patching
Description: no drug/ patching